HGG-19. CLINICAL RESPONSE TO THE PDGFRA/KIT INHIBITOR AVAPRITINIB IN PEDIATRIC AND YOUNG ADULT HIGH-GRADE GLIOMA PATIENTS WITH H3K27M OR PDGFRA GENOMIC ALTERATIONS
Authors: Trissal Maria , Mayr Lisa , Schwark Kallen , LaBelle Jenna , Kong Seongbae , Furtner Julia , Weiler-Wichtl Liesa , Supko Jeffrey , Rozowsky Jacob , Hack Olivia , Groves Andrew , Marques Joana , Leiss Ulrike , Rosenmayr Verena , Dubois Frank , Greenwald Noah F , Madlener Sibylle , Guntner Armin Sebastian , Pálová Hana , Stepien Natalia , Lötsch-Gojo Daniela , Dorfer Christian , Dieckmann Karen , Peyrl Andreas , Azizi Amadeo A , Baumgartner Alicia , Slabý Ondřej , Pokorná Petra , Bandopadhayay Pratiti , Rameen_Beroukhim@dfci.harvard.edu Beroukhim Rameen Beroukhim , Ligon Keith L , Kramm Christof M , Bronsema Annika , Bailey Simon , Stucklin Ana Guerreiro , Mueller Sabine Mueller , Jones David T W , Jäger Natalie , Mullauer Leonhard , Haberler Christine , Kumar-Sinha Chandan , Chinnaiyan Arul , Mody Rajen , Sterba.Jaroslav@fnbrno.cz Štěrba Jaroslav Štěrba , Skrypek Mary , Martinez Nina , Bowers Daniel C , Koschmann Carl Koschmann , Gojo Johannes , Filbin Mariella 
Published: June 2023

PDGFRA is commonly altered in pediatric and young adult high-grade gliomas (pHGGs) including histone 3 lysine 27-mutated diffuse midline gliomas (H3K27M DMG), a fatal disease with no current options for cure. We performed comprehensive genomic and transcriptomic analyses of n=259 pediatric high-grade glioma cases which revealed PDGFRA genomic alterations in ~15% of patients. H3K27M DMGs had significantly higher PDGFRA expression compared to H3 wild-type tumors regardless of genomic alteration. Tumors with PDGFRA gene amplification demonstrated significantly elevated PDGFRA expression in both H3K27M DMGs and H3 wild-type pHGGs relative to tumors with wild-type or point mutated PDGFRA. We tested a range of PDGFRA inhibitors against a panel of patient derived pediatric H3K27M DMG, pHGG, and adult HGG. Amongst the inhibitors tested, avapritinib, a potent small molecule inhibitor with relatively selective activity against both wild-type and mutant PDGFRA showed potent toxicity against a wide array of pediatric and adult cell lines. This molecule also demonstrated supra-micromolar blood brain barrier penetration in pre-clinical in vivo models, and demonstrated significant decrease in tumor growth and improved survival in orthotopic mouse xenograft models. Finally, building on this preclinical activity, we report the first clinical experience using avapritinib in eight pediatric and young adult patients with high-grade glioma (H3K27M DMG and/or PDGFRA altered). Avapritinib usage showed no significant acute toxicities within this patient cohort. Most importantly, our preliminary data reveal radiographic response evaluated by RAPNO criteria in 50% of patients, a striking outcome rarely seen in this patient population. In summary, we report that avapritinib, a selective, CNS penetrant small molecule inhibitor of PDGFRA has potent activity in preclinical models and produced promising clinical responses with good tolerability in pediatric and young adult patients with high-grade glioma, suggesting a promising role for avapritinib therapy in pediatric high grade glioma.